| ISOFOL Stock | | | SEK 2.99 0.11 3.82% |
CFO
Mr. Gustaf Albert was appointed Chief Financial Officer at Isofol Medical AB effective as of November 1, 2017. He joins Isofol from a previous position as the CEO of Elanders Sverige AB, a subsidiary of Elanders AB listed at Nasdaq Stockholm Mid Cap. Prior to his employment at Elanders, Albert worked for Deloitte as an authorized auditor, where he coordinated major Swedish and international audit assignments. since 2017.
| Tenure | 7 years |
| Phone | 46 3 17 97 22 80 |
| Web | https://isofolmedical.com |
Isofol Medical Management Efficiency
The company has return on total asset
(ROA) of
(0.3605) % which means that it has lost $0.3605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.6945) %, meaning that it generated substantial loss on money invested by shareholders. Isofol Medical's management efficiency ratios could be used to measure how well Isofol Medical manages its routine affairs as well as how well it operates its assets and liabilities.
Isofol Medical AB has accumulated 110
K in total debt with debt to equity ratio
(D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Isofol Medical AB has a current ratio of 1.19, suggesting that it
may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Isofol Medical until it has trouble settling it off, either with new capital or with free cash flow. So, Isofol Medical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Isofol Medical AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Isofol to invest in growth at high rates of return. When we think about Isofol Medical's use of debt, we should always consider it together with cash and equity.
Similar Executives
Isofol Medical AB , a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden. Isofol Medical operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people. Isofol Medical AB (ISOFOL) is traded on Stockholm Exchange in Sweden and employs 15 people.
Management Performance
Isofol Medical AB Leadership Team
Elected by the shareholders, the Isofol Medical's board of directors comprises two types of representatives: Isofol Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Isofol. The board's role is to monitor Isofol Medical's management team and ensure that shareholders' interests are well served. Isofol Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Isofol Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ParOla Mannefred, Chairman of the Board | |
| Gustaf MSc, CFO CEO | |
| Magnus Bjorsne, Director | |
| Roger Tell, Chief Medical Officer, Chief Scientific Officer | |
| Karin Ganlov, Senior Medical Director | |
| Paula Boultbee, Director | |
| Anna Belfrage, Director | |
| Jarl MD, CEO MD | |
| Robert Marchesani, Director | |
| Alain Herrera, Director | |
| Jarl Jungnelius, Chief Executive Officer, Director | |
| Roger MD, Chief Officer | |
| Jenny Sundqvist, Chief Officer | |
| Gustaf Albert, Chief Financial Officer | |
Isofol Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Isofol Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Other Information on Investing in Isofol Stock
Isofol Medical financial ratios help investors to determine whether Isofol Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isofol with respect to the benefits of owning Isofol Medical security.